GlassScriptPhysician profile
Kenny Perez
NPI 1730524307
$452,897.13
in general payments reported to CMS, 2019-2025
25 companies · $212K in 2025
The $212K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2021: $649 · 2022: $58K · 2023: $27K · 2024: $154K · 2025: $212K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $219K · Honoraria: $79K · Consulting Fee: $47K · Travel and Lodging: $39K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $218,701.00 |
| Honoraria | $79,475.00 |
| Consulting Fee | $46,770.00 |
| Travel and Lodging | $38,541.96 |
| Food and Beverage | $10,144.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $239,894.17 | 2022-2025 | Spravato |
| Axsome Therapeutics, INC. | $120,478.81 | 2023-2025 | Auvelity |
| Corium, LLC | $90,475.85 | 2021-2025 | Azstarys, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $446.40 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $249.84 | 2021 | |
| Neuronetics, INC. | $195.44 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $175.00 | 2019 | |
| Alkermes, INC. | $161.10 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $120.87 | 2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $97.87 | 2022 | |
| Lundbeck LLC | $78.74 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $74.56 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $73.93 | 2025 | Cobenfy |
| Almatica Pharma LLC | $70.04 | 2023-2024 | Loreev Xr, Sertraline Hcl, Venlafaxine |
| Abbvie INC. | $46.74 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $45.03 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $36.53 | 2023 | Jornay Pm |
| Neos Therapeutics, LP | $31.64 | 2024 | Adzenys Xr-Odt |
| Tempus Ai, INC | $27.85 | 2024 | |
| Tris Pharma INC | $24.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.81 | 2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $20.54 | 2023 | Qelbree |
| Sage Therapeutics, LLC | $19.15 | 2023 | |
| Livanova USA, INC. | $15.90 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Vertical Pharmaceuticals, LLC | $13.33 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenny Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.